{
  "docId": "019de075-8a55-750a-8008-603750933d71",
  "docSlug": "da8608bdf4ad385699d1340db7dce185",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 54,
  "pageCount": 56,
  "prevPage": 53,
  "nextPage": 55,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a comparison frame to position ERAS-601 against competitors like Novartis, Revolution Medicines, Jacobio, Genentech, Pfizer, and Merck.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/54",
  "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
  "deckJsonHref": "/decks/019de075-8a55-750a-8008-603750933d71.json",
  "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-54",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.38,
        "x": 0.13,
        "y": 0.155
      },
      "kind": "diagram",
      "text": "Clinical landscape of SHP2 inhibitors",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0a2a960-f02d-449e-bb3d-748afe017c1e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.415,
        "x": 0.533,
        "y": 0.805
      },
      "kind": "disclaimer",
      "text": "LVEF: left ventricular ejection fraction; cetux: cetuximab; osi: osimertinib; PR: partial response; cPR: confirmed partial response",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0857fc91-81ca-4922-a2ad-946534dbf0c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.415,
        "x": 0.533,
        "y": 0.215
      },
      "kind": "list",
      "text": "Strong potency, favorable ADME/PK; Clinical safety and tolerability profile; Encouraging signs of clinical efficacy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1be538f2-78d7-4c66-bbe4-4f643eefa8fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "ERAS-601: Potential best-in-class SHP2i, favorable profile for combination",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c42e5c9-817d-4e54-abc5-eae9d126c02c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "6b79ae27-c8e2-4e94-ac21-af6516c6c493",
      "evidence": "Compares ERAS-601 against multiple industry competitors in a structured grid.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}